An independent two-stage DCF analysis by a frontier AI model.
Kenvue's intrinsic value is anchored by its unparalleled portfolio of iconic consumer health brands—Tylenol, Listerine, Band-Aid, and Neutrogena—which occupy nearly unshakable positions in consumer medicine cabinets globally. This incredible brand equity, built over decades under Johnson & Johnson, provides the company with a highly defensive, recession-resistant revenue stream and massive, predictable free cash flow. The core thesis relies on the non-discretionary nature of these products; regardless of the economic environment, consumers will continue to purchase pain relievers and basic healthcare necessities.
However, the path to significant capital appreciation is currently murky. The company is experiencing sluggish volume growth as the cumulative effect of price increases has driven some consumers toward private-label alternatives. Furthermore, its Skin Health and Beauty segment is underperforming amidst intense competition. While the robust dividend yield provides a solid floor and income for patient investors, Kenvue currently lacks the top-line momentum necessary to drive a premium valuation. It is a quintessential 'cash cow' that must prove it can reignite organic volume growth to unlock further shareholder value.
A conservative 3.5% growth rate is modeled, reflecting the struggles with volume growth and the mature, slow-growing nature of the core consumer health categories it dominates.
A low 7.5% discount rate is utilized, recognizing Kenvue's highly defensive business model, the non-discretionary nature of its products, and its robust, predictable cash flow generation.
A 2.0% terminal growth rate assumes the company will grow slightly below the rate of long-term GDP, typical for a mature, slow-growth consumer packaged goods conglomerate.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $20.17 | $16.50 | $13.96 | $12.10 | $10.68 |
| 1.5% | $22.69 | $18.15 | $15.13 | $12.96 | $11.34 |
| 2.0% | $25.93 | $20.17 | $16.50 | $13.96 | $12.10 |
| 2.5% | $30.25 | $22.69 | $18.15 | $15.13 | $12.96 |
| 3.0% | $36.30 | $25.93 | $20.17 | $16.50 | $13.96 |
■ Undervalued vs current price ■ Overvalued vs current price
The 3.5% growth rate reflects the reality of Kenvue's mature end markets and its recent struggles to maintain sales volume amidst significant price increases and consumer trading-down behavior.
During the spin-off, Johnson & Johnson retained the vast majority of talc-related liabilities arising from events prior to the separation. This significantly insulates Kenvue's cash flows from that specific massive legal overhang.
It borders on it. While the brands are exceptional and the cash flow is real, the lack of top-line growth means returns will likely be heavily dependent on the dividend yield rather than significant capital appreciation until management can demonstrate a turnaround in volumes.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.